We invite you to listen to an in-depth discussion of Question #1 and Question #2 in the CIBRN community on Sosido, as presented by Dr. Vipul Jairath and Dr. David Morgan, recorded at the CIBRN Gastroenterology Webinar, November 24, 2016. Link to recorded webinar.
Question #1: Based on data presented so far, is there sufficient evidence to consider non-medical switching of biologics in stable patients on treatment? If no, what data would you wish to see before you do this in your clinical practice. Link to discussion on Sosido.
Question #2: Based on data published to this point, when starting a patient on infliximab do you think we should be using originator molecules, only biosimilars or either molecule in naïve patients? What factors influence your considerations? Link to discussion on Sosido.
Please join Dr. Vipul Jairath and Dr. David Morgan for an hour-long webinar to discuss and deep dive on CIBRN Question 1 & Question 2 surrounding the implications of the evolving Biosimilar landscape on clinical practice and patient health.
This webinar is intended for the CIBRN Gastroenterology subgroup and is scheduled for Thursday, November 24th 7:30-8:30pm EST. See instructions below:
Step 1: To join the audio portion:
Dial toll-free: 1-866-830-9434
Enter Participant Code: 7994216
Step 2: To join the web portion:
Click on link: https://studio7communications.adobeconnect.com/cibrn_gastroenterology
Enter your name
Prior to the webinar, you are invited to visit the CIBRN community on Sosido to review the questions & responses and to reply with your personal clinical perspectives. The webinar will be recorded and archived for future viewing by the CIBRN community.
If you have any comments or questions, please contact firstname.lastname@example.org
If you have never attended an Adobe Connect meeting before:
Test your connection: https://studio7communications.adobeconnect.com/common/help/en/support/meeting_test.htm
Get a quick overview: http://www.adobe.com/products/adobeconnect.html
Canadian Immunology and Biologics Research Network launches this week, supporting open scientific discussion around immunology and biologics research.
We’re delighted to announce the launch of a new initiative called the Canadian Immunology and Biologics Research Network (CIBRN).
CIBRN is conceived as a learning community fostering open scientific discussions through online forums, webinars and MicroLearning objects. The intent is for members with an interest in Immunology and Biologics research to sustain an ongoing connection and, anchored in scientific discovery & expert insight, share clinical findings and professional perspectives to advance understanding in this field. In addition, we see this community as a platform for peer-to-peer discussions post-NIBRT to ensure the highest level of care for patients in Canada.
LegitiMed will be managing this community residing on Sosido (www.sosido.com). Learning will be structured and unstructured with specific objectives related to current & imminent topics in this field, for example, the biosimilar medical switch debate and clinical implications.
Some details about your participation:
- Sosido will set up your account, monitor your publications, and alert you when a new publication you’ve authored will be featured in the CIBRN community;
- You will receive a weekly email digest with a summary of all new research from members of the CIBRN community, as well as abstracts from key immunology journals;
- You will also have access to a private online discussion forum if you wish to reach out to others in the CIBRN community to ask or answer questions;
- We understand that your level of participation will be determined by your level of interest. As such, if you find that the network is not useful to you or you do not want your research to be featured, you can unsubscribe at any time.
We are interested in a full exchange of ideas around this subject and welcome others who would be interested in participating in CIBRN. To participate, please contact email@example.com.
We thank AbbVie Canada for their financial support of this initiative.